Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 152

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 152
---
arni that are 
 currently exercisable or will become exercisable within 60 days of the Record Date.                      |

| (11) | Consists of 92,816 Common Shares issuable upon the exercise of options granted to Dr. Molineaux that are 
 currently exercisable or will become exercisable within 60 days of the Record Date.                      |

| (12) | Consists of (a) 4,000 Common Shares held by Ms. Rhoads and (b) 163,307 Common Shares issuable upon the                                 
 exercise of options granted to Ms. Rhoads that are currently exercisable or will become exercisable within 60 days of the Record Date. |

| (13) | Consists of (a) 8,000 Common Shares held by Ms. Schafer and (b) 195,333 Common Shares issuable upon the                                 
 exercise of options granted to Ms. Schafer that are currently exercisable or will become exercisable within 60 days of the Record Date. |

| (14) | Consists of 28,711 Common Shares issuable upon the exercise of options granted to Dr. Stein that are 
 currently exercisable or will become exercisable within 60 days of the Record Date.                  |

| (15) | Consists of (a) 3,428,867 Common Shares beneficially owned by our directors and executive officers and (b)                                                                                                         
 2,305,588 Common Shares issuable upon the exercise of options granted to our current executive officers and directors that are currently exercisable or will become exercisable within 60 days of the Record Date. |

The direct and indirect benefits of accepting or refusing the Arrangement to any of the beneficial owners provided in the table above are described in this Circular and Proxy Statement. See sections entitled “ The Arrangement — Background of the Arrangement” and “ The Arrangement — Recommendation of the Transaction Committee; Reasons for the Arrangement; Recommendation of the Board; and Opinion of Leerink Partners.” 93

DELISTING AND DEREGISTRATION OF COMMON SHARES

If the Arrangement is completed, the Common Shares will be delisted from Nasdaq and deregistered under the Exchange Act, in each case, in
accordance with applicable laws, rules and regulations. As a result, we will no longer file periodic reports with the SEC on account of the Common Shares. In addition, following the Effective Time, the Company is expected to apply to file an
application with